Sequenced, Not Stirred: Positioning CAR T and Bispecific Antibody Therapy in Multiple Myeloma.

IF 12.2 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2026-09-03 DOI:10.1158/2643-3230.BCD-26-0256

Rahul Banerjee

引用次数: 0

Abstract

In this issue of Blood Cancer Discovery, Merz and colleagues study more than 600 recipients of chimeric antigen receptor T-cell (CAR T) and/or bispecific antibody therapy in multiple myeloma with an emphasis on patients who received both modalities sequentially. They find a clear progression-free survival advantage when CAR T therapy was used first; importantly, because outcomes with both modalities were similar when following progression after the converse modality, this advantage was driven by CAR T therapy's up-front benefits. See related article by Merz et al, p. 697.

查看原文本刊更多论文

测序，不搅拌：定位CAR - T和双特异性抗体治疗多发性骨髓瘤。

在这一期的《血癌发现》中，Merz和他的同事研究了600多名接受CAR - T和/或双特异性抗体治疗的多发性骨髓瘤患者，重点是先后接受两种治疗方式的患者。他们发现首次使用CAR - T治疗有明显的无进展生存优势；重要的是，由于两种方式的结果在反向方式后的进展相似，这种优势是由CAR - T治疗的前期益处驱动的。参见Merz等人的相关文章，第XX页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.